• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
27
Feb
2017

You Can’t Do That With RNA, Can You? Arrakis Tests Small Molecules in a New Way

/
Luke Timmerman
/
3
/
All, Science, Strategy, The Edge
27 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Feb
2017

BMS on the Block (Maybe), Sarepta Sells a Golden Ticket to Gilead & a Summit Pic

/
Luke Timmerman
/
0
/
All
24 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Feb
2017

Why Every Biopharma Lab Should Have a 3D Printer (and a Laser Cutter Too)

/
Kyle Serikawa
/
0
/
All, Strategy
21 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Feb
2017

Hiring Women Execs in Biotech, VC Firms Is a Moneyball Play (Part 2)  

/
Leora Schiff & Kyle Serikawa
/
0
/
All, People
17 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
16
Feb
2017

The Road Not Traveled: Journey of a PhD into the Biotech Business and Finance Industry

/
Luke Lee
/
2
/
All, People, Venture Capital
16 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Feb
2017

Now More Than Ever: The Need for Personalized Medicine in Immuno-Oncology

/
Sarah Warren & Jason Reeves
/
0
/
All, Cancer, Diagnostics
13 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
10
Feb
2017

Pulse Check on Patient-Centricity: 7 Vital Signs

/
Kim McCleary
/
0
/
All, People, Strategy
10 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Feb
2017

Changing Small Molecule Exclusivity Rules as a Long-Term Drug Price Policy

/
Kyle Serikawa
/
2
/
All, Politics
08 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Feb
2017

Join Me at BIO-Europe Spring Mar. 21 in Barcelona To Talk EU Entrepreneurship

/
Luke Timmerman
/
0
/
All, Strategy, Venture Capital
07 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Feb
2017

A Canadian Biotech Breakaway?

/
Asher Mullard
/
0
/
All, Finance, Strategy, Venture Capital
06 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Feb
2017

Hiring Women Execs in Biotech, VC Firms is a Moneyball Play (Part 1): Getting Better Returns

/
Leora Schiff & Kyle Serikawa
/
1
/
All, People, Politics
03 Feb 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Jan
2017

Drug Delivery Devices Tantalize with Promise in Adherence, Local Delivery and Personalization

/
Stacy Lawrence
/
0
/
All, Devices, Drugs
30 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
Jan
2017

J&J Reels in Actelion for $30B, Celgene Snaps up Delinia, and an IPO Flurry

/
Luke Timmerman
/
0
/
All
27 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
26
Jan
2017

Conversation with Steve Miller on The Evolving Relationship of PBMs and Biopharma (Part 2)

/
Leora Schiff
/
0
/
All, Payers
26 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
25
Jan
2017

Conversation with Steve Miller of Express Scripts (Part 1)

/
Leora Schiff
/
3
/
All, Payers
25 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Jan
2017

Women Making Progress, Very Slowly, On Biotech Boards, Report Says

/
Luke Timmerman
/
1
/
All, People
24 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
23
Jan
2017

It Takes Two: Universities and Industry Can Work Together to Fix the PhD Job Market

/
Boaz Vilozny
/
0
/
All, People
23 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Jan
2017

Who’s In and Out on Trump’s Health Team, BMS Cedes Ground to Merck, & CRE Superbugs on the Move

/
Luke Timmerman
/
0
/
All
20 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
Jan
2017

Takeda Leans on a Little Guy, Ovid Therapeutics, to Go the Distance With an Epilepsy Drug

/
Luke Timmerman
/
1
/
All, Strategy
18 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
13
Jan
2017

Takeda Takes Out Ariad, Illumina Plants a $100 Genome Stake, & Anti-Vaxxer Nuzzles With Trump

/
Luke Timmerman
/
0
/
All, Politics
13 Jan 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 64 65 66 67 68 … 79 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder